Clinical trial
A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia
NCT03301597 is registered in ClinicalTrials.gov with Nohla Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia
- Lead sponsor
- Nohla Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 24, 2018
- Completion date
- March 18, 2019
- Enrollment
- 146 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.